25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ACADIA Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Acadia together

I guess you are interested in ACADIA Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ACADIA Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about ACADIA Pharmaceuticals Inc

I send you an email if I find something interesting about ACADIA Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Acadia (30 sec.)










1.2. What can you expect buying and holding a share of Acadia? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.47
Expected worth in 1 year
$4.76
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$1.29
Return On Investment
7.5%

For what price can you sell your share?

Current Price per Share
$17.26
Expected price per share
$14.41 - $20.42
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Acadia (5 min.)




Live pricePrice per Share (EOD)
$17.26
Intrinsic Value Per Share
$1.38 - $26.31
Total Value Per Share
$4.85 - $29.78

2.2. Growth of Acadia (5 min.)




Is Acadia growing?

Current yearPrevious yearGrowGrow %
How rich?$577.1m$383.1m$114.2m23.0%

How much money is Acadia making?

Current yearPrevious yearGrowGrow %
Making money$32.1m-$37.2m$69.3m215.8%
Net Profit Margin13.7%-24.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Acadia (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#103 / 944

Most Revenue
#45 / 944

Most Profit
#40 / 944
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Acadia?

Welcome investor! Acadia's management wants to use your money to grow the business. In return you get a share of Acadia.

First you should know what it really means to hold a share of Acadia. And how you can make/lose money.

Speculation

The Price per Share of Acadia is $17.26. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acadia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acadia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.47. Based on the TTM, the Book Value Change Per Share is $0.32 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acadia.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.201.1%0.191.1%-0.32-1.9%-0.23-1.3%-0.29-1.7%
Usd Book Value Change Per Share0.362.1%0.321.9%-0.10-0.6%-0.03-0.2%0.040.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.362.1%0.321.9%-0.10-0.6%-0.03-0.2%0.040.2%
Usd Price Per Share15.38-20.36-19.88-26.70-28.11-
Price to Earnings Ratio19.53-28.69--15.66--13.18--18.20-
Price-to-Total Gains Ratio42.31-66.13--35.66-7.00--52.74-
Price to Book Ratio4.43-7.10-8.66-8.42-11.42-
Price-to-Total Gains Ratio42.31-66.13--35.66-7.00--52.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.26
Number of shares57
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.32-0.03
Usd Total Gains Per Share0.32-0.03
Gains per Quarter (57 shares)18.41-1.92
Gains per Year (57 shares)73.65-7.68
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1074640-8-18
201471380-15-26
302212120-23-34
402952860-31-42
503683600-38-50
604424340-46-58
705165080-54-66
805895820-61-74
906636560-69-82
1007377300-77-90

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%4.08.00.033.3%4.016.00.020.0%4.036.00.010.0%5.079.01.05.9%
Book Value Change Per Share4.00.00.0100.0%5.07.00.041.7%8.012.00.040.0%12.028.00.030.0%26.059.00.030.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.085.00.0%
Total Gains per Share4.00.00.0100.0%5.07.00.041.7%8.012.00.040.0%12.028.00.030.0%26.059.00.030.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of ACADIA Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3630.323+13%-0.095+126%-0.034+109%0.037+881%
Book Value Per Share--3.4692.988+16%2.303+51%3.114+11%2.696+29%
Current Ratio--2.2922.229+3%2.822-19%5.051-55%8.377-73%
Debt To Asset Ratio--0.4090.431-5%0.390+5%0.290+41%0.195+110%
Debt To Equity Ratio--0.6920.760-9%0.647+7%0.445+56%0.279+149%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--2724750960.0003506894082.500-22%3447090440.000-21%4745920996.500-43%4999046538.250-45%
Eps--0.1970.193+2%-0.323+264%-0.229+216%-0.292+248%
Ev To Ebitda Ratio--21.52729.337-27%73.121-71%3.875+455%-10.313+148%
Ev To Sales Ratio--2.7203.808-29%5.636-52%9.366-71%66292.594-100%
Free Cash Flow Per Share--0.3800.304+25%-0.199+152%-0.096+125%-0.179+147%
Free Cash Flow To Equity Per Share--0.3810.320+19%-0.167+144%-0.042+111%0.031+1137%
Gross Profit Margin--1.0000.949+5%1.033-3%1.081-8%1.061-6%
Intrinsic Value_10Y_max--26.311--------
Intrinsic Value_10Y_min--1.385--------
Intrinsic Value_1Y_max--0.308--------
Intrinsic Value_1Y_min---0.575--------
Intrinsic Value_3Y_max--2.700--------
Intrinsic Value_3Y_min---1.120--------
Intrinsic Value_5Y_max--7.231--------
Intrinsic Value_5Y_min---0.995--------
Market Cap2871925920.000+11%2559108960.0003389316582.500-24%3308288940.000-23%4442898296.500-42%4676979088.250-45%
Net Profit Margin--0.1310.137-4%-0.242+285%-0.323+347%-1674.667+1279936%
Operating Margin---0.088-100%-0.2680%-0.3470%-1682.8740%
Operating Ratio--0.8740.881-1%1.261-31%1.337-35%2441.995-100%
Pb Ratio4.976+11%4.4347.095-38%8.656-49%8.425-47%11.420-61%
Pe Ratio21.913+11%19.52628.689-32%-15.664+180%-13.181+168%-18.197+193%
Price Per Share17.260+11%15.38020.358-24%19.883-23%26.699-42%28.107-45%
Price To Free Cash Flow Ratio11.365+11%10.12719.726-49%-29.360+390%-73.162+822%-53.290+626%
Price To Total Gains Ratio47.486+11%42.31366.134-36%-35.659+184%6.995+505%-52.739+225%
Quick Ratio--3.1222.883+8%3.996-22%7.318-57%13.193-76%
Return On Assets--0.0340.038-11%-0.059+277%-0.052+254%-0.100+398%
Return On Equity--0.0570.066-14%-0.099+275%-0.067+218%-0.117+305%
Total Gains Per Share--0.3630.323+13%-0.095+126%-0.034+109%0.037+881%
Usd Book Value--577180000.000497419750.000+16%383159500.000+51%518217350.000+11%448640900.000+29%
Usd Book Value Change Per Share--0.3630.323+13%-0.095+126%-0.034+109%0.037+881%
Usd Book Value Per Share--3.4692.988+16%2.303+51%3.114+11%2.696+29%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--2724750960.0003506894082.500-22%3447090440.000-21%4745920996.500-43%4999046538.250-45%
Usd Eps--0.1970.193+2%-0.323+264%-0.229+216%-0.292+248%
Usd Free Cash Flow--63176000.00050664250.000+25%-33147750.000+152%-16028200.000+125%-29823525.000+147%
Usd Free Cash Flow Per Share--0.3800.304+25%-0.199+152%-0.096+125%-0.179+147%
Usd Free Cash Flow To Equity Per Share--0.3810.320+19%-0.167+144%-0.042+111%0.031+1137%
Usd Market Cap2871925920.000+11%2559108960.0003389316582.500-24%3308288940.000-23%4442898296.500-42%4676979088.250-45%
Usd Price Per Share17.260+11%15.38020.358-24%19.883-23%26.699-42%28.107-45%
Usd Profit--32765000.00032126500.000+2%-37202000.000+214%-34852100.000+206%-46951550.000+243%
Usd Revenue--250401000.000232309000.000+8%157971500.000+59%148304650.000+69%89324750.000+180%
Usd Total Gains Per Share--0.3630.323+13%-0.095+126%-0.034+109%0.037+881%
 EOD+4 -4MRQTTM+26 -12YOY+23 -145Y+24 -1310Y+24 -13

3.3 Fundamental Score

Let's check the fundamental score of ACADIA Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.913
Price to Book Ratio (EOD)Between0-14.976
Net Profit Margin (MRQ)Greater than00.131
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.122
Current Ratio (MRQ)Greater than12.292
Debt to Asset Ratio (MRQ)Less than10.409
Debt to Equity Ratio (MRQ)Less than10.692
Return on Equity (MRQ)Greater than0.150.057
Return on Assets (MRQ)Greater than0.050.034
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of ACADIA Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.736
Ma 20Greater thanMa 5016.905
Ma 50Greater thanMa 10015.979
Ma 100Greater thanMa 20016.167
OpenGreater thanClose17.260
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-12-05 11:14:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Acadia earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Net Profit Margin of 13.1% means that $0.13 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 13.1%. The company is making a huge profit. +2
  • The TTM is 13.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ13.1%TTM13.7%-0.6%
TTM13.7%YOY-24.2%+37.9%
TTM13.7%5Y-32.3%+46.0%
5Y-32.3%10Y-167,466.7%+167,434.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.1%-108.6%+121.7%
TTM13.7%-221.4%+235.1%
YOY-24.2%-207.4%+183.2%
5Y-32.3%-346.2%+313.9%
10Y-167,466.7%-470.4%-166,996.3%
4.3.1.2. Return on Assets

Shows how efficient Acadia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • 3.4% Return on Assets means that Acadia generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 3.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.4%TTM3.8%-0.4%
TTM3.8%YOY-5.9%+9.7%
TTM3.8%5Y-5.2%+8.9%
5Y-5.2%10Y-10.0%+4.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4%-11.6%+15.0%
TTM3.8%-12.0%+15.8%
YOY-5.9%-11.2%+5.3%
5Y-5.2%-12.6%+7.4%
10Y-10.0%-14.1%+4.1%
4.3.1.3. Return on Equity

Shows how efficient Acadia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • 5.7% Return on Equity means Acadia generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 5.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.6%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.7%TTM6.6%-0.9%
TTM6.6%YOY-9.9%+16.5%
TTM6.6%5Y-6.7%+13.3%
5Y-6.7%10Y-11.7%+5.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.7%-14.5%+20.2%
TTM6.6%-16.0%+22.6%
YOY-9.9%-14.6%+4.7%
5Y-6.7%-18.5%+11.8%
10Y-11.7%-19.2%+7.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of ACADIA Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Acadia is operating .

  • Measures how much profit Acadia makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8.8%-8.8%
TTM8.8%YOY-26.8%+35.5%
TTM8.8%5Y-34.7%+43.5%
5Y-34.7%10Y-168,287.4%+168,252.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.0%+204.0%
TTM8.8%-316.8%+325.6%
YOY-26.8%-215.6%+188.8%
5Y-34.7%-376.1%+341.4%
10Y-168,287.4%-480.3%-167,807.1%
4.3.2.2. Operating Ratio

Measures how efficient Acadia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.87 means that the operating costs are $0.87 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.874. The company is less efficient in keeping operating costs low.
  • The TTM is 0.881. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.874TTM0.881-0.007
TTM0.881YOY1.261-0.380
TTM0.8815Y1.337-0.456
5Y1.33710Y2,441.995-2,440.659
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8742.284-1.410
TTM0.8813.198-2.317
YOY1.2613.247-1.986
5Y1.3374.651-3.314
10Y2,441.9956.419+2,435.576
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of ACADIA Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Acadia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.29 means the company has $2.29 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 2.292. The company is able to pay all its short-term debts. +1
  • The TTM is 2.229. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.292TTM2.229+0.063
TTM2.229YOY2.822-0.593
TTM2.2295Y5.051-2.822
5Y5.05110Y8.377-3.326
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2923.586-1.294
TTM2.2293.869-1.640
YOY2.8224.644-1.822
5Y5.0515.971-0.920
10Y8.3776.240+2.137
4.4.3.2. Quick Ratio

Measures if Acadia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Quick Ratio of 3.12 means the company can pay off $3.12 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 3.122. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.883. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.122TTM2.883+0.239
TTM2.883YOY3.996-1.113
TTM2.8835Y7.318-4.435
5Y7.31810Y13.193-5.874
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1223.093+0.029
TTM2.8833.392-0.509
YOY3.9964.304-0.308
5Y7.3185.953+1.365
10Y13.1936.435+6.758
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of ACADIA Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Acadia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acadia to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.41 means that Acadia assets are financed with 40.9% credit (debt) and the remaining percentage (100% - 40.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.409. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.431. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.409TTM0.431-0.022
TTM0.431YOY0.390+0.041
TTM0.4315Y0.290+0.141
5Y0.29010Y0.195+0.095
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4090.346+0.063
TTM0.4310.347+0.084
YOY0.3900.313+0.077
5Y0.2900.365-0.075
10Y0.1950.383-0.188
4.5.4.2. Debt to Equity Ratio

Measures if Acadia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Debt to Equity ratio of 69.2% means that company has $0.69 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.692. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.760. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.692TTM0.760-0.067
TTM0.760YOY0.647+0.112
TTM0.7605Y0.445+0.315
5Y0.44510Y0.279+0.166
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6920.393+0.299
TTM0.7600.432+0.328
YOY0.6470.388+0.259
5Y0.4450.455-0.010
10Y0.2790.498-0.219
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acadia generates.

  • Above 15 is considered overpriced but always compare Acadia to the Biotechnology industry mean.
  • A PE ratio of 19.53 means the investor is paying $19.53 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 21.913. Based on the earnings, the company is fair priced.
  • The MRQ is 19.526. Based on the earnings, the company is fair priced.
  • The TTM is 28.689. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD21.913MRQ19.526+2.387
MRQ19.526TTM28.689-9.163
TTM28.689YOY-15.664+44.353
TTM28.6895Y-13.181+41.870
5Y-13.18110Y-18.197+5.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD21.913-2.180+24.093
MRQ19.526-2.507+22.033
TTM28.689-3.153+31.842
YOY-15.664-3.242-12.422
5Y-13.181-5.992-7.189
10Y-18.197-6.690-11.507
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 11.365. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 10.127. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 19.726. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD11.365MRQ10.127+1.238
MRQ10.127TTM19.726-9.599
TTM19.726YOY-29.360+49.086
TTM19.7265Y-73.162+92.887
5Y-73.16210Y-53.290-19.872
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD11.365-2.879+14.244
MRQ10.127-3.276+13.403
TTM19.726-3.669+23.395
YOY-29.360-4.485-24.875
5Y-73.162-8.015-65.147
10Y-53.290-9.197-44.093
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Acadia is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.43 means the investor is paying $4.43 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 4.976. Based on the equity, the company is fair priced.
  • The MRQ is 4.434. Based on the equity, the company is fair priced.
  • The TTM is 7.095. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.976MRQ4.434+0.542
MRQ4.434TTM7.095-2.661
TTM7.095YOY8.656-1.561
TTM7.0955Y8.425-1.330
5Y8.42510Y11.420-2.995
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.9761.964+3.012
MRQ4.4342.056+2.378
TTM7.0952.388+4.707
YOY8.6562.460+6.196
5Y8.4253.697+4.728
10Y11.4204.324+7.096
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ACADIA Pharmaceuticals Inc.

4.8.1. Institutions holding ACADIA Pharmaceuticals Inc

Institutions are holding 97.062% of the shares of ACADIA Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Baker Bros Advisors LP25.76926.83474287791600
2024-09-30Vanguard Group Inc8.31960.0038138431961310650.9558
2024-09-30RTW INVESTMENTS, LLC8.23813.05051370750600
2024-06-30BlackRock Inc7.24930.0044120622133934733.372
2024-09-30State Street Corp3.59020.003759738741730842.9838
2024-09-30D. E. Shaw & Co LP2.10640.0463350495757003119.4223
2024-09-30Fred Alger Management, LLC1.9150.2376318638948195017.8207
2024-09-30Geode Capital Management, LLC1.72820.00362875540308261.0836
2024-09-30Palo Alto Investors, LLC1.51695.042225239561051154.3457
2024-09-30First Trust Advisors L.P.1.27760.03122125874575542.7826
2024-09-30Millennium Management LLC1.23390.0152053119-884595-30.1117
2024-09-30Goldman Sachs Group Inc1.05710.0044175885941791531.1657
2024-09-30Morgan Stanley - Brokerage Accounts1.00720.00191675854-3106356-64.9565
2024-09-30TANG CAPITAL MANAGEMENT LLC0.90151.648150000000
2024-06-30NORGES BANK0.87230.0035145148382650.5727
2024-09-30Nuveen Asset Management, LLC0.81910.00591362985921136208.473
2024-09-30VOLORIDGE INVESTMENT MANAGEMENT, LLC0.78670.07331308993-292223-18.2501
2024-09-30Man Group PLC0.76650.0511127543312182882131.9241
2024-09-30Charles Schwab Investment Management Inc0.76390.00371271135-4144-0.3249
2024-06-30Deutsche Bank AG0.74650.0091124219421396320.8088
Total 70.665217.0739117581476+435347+0.4%

4.9.2. Funds holding ACADIA Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv2.32040.00333860983-29581-0.7603
2024-11-27iShares Russell 2000 ETF1.9930.0673316191-6930-0.2085
2024-11-27SPDR® S&P Biotech ETF1.8820.68733131463-95040-2.9456
2024-10-31Vanguard Small Cap Index1.87790.03312470661000.1956
2024-11-28First Trust NYSE Arca Biotech ETF1.57363.5885261838900
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.1160.0251856957-5201-0.2793
2024-10-31Vanguard Small Cap Growth Index Inv1.02870.06881711601-5818-0.3388
2024-08-31Fidelity Small Cap Index0.73630.07451225198-28970-2.3099
2024-11-27iShares Biotechnology ETF0.68160.2652113419011530.1018
2024-11-27iShares Russell 2000 Growth ETF0.64980.1317108117800
2024-08-31Alger Weatherbie Specialized Growth A0.51472.8077856379473445.8519
2024-08-31Biotech Growth Ord0.45952.699176460000
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.43870.0237729955-26200-3.4649
2024-09-30Vanguard Strategic Equity Inv0.43230.122271930900
2024-09-30Fidelity Extended Market Index0.4290.0263713835-13807-1.8975
2024-04-15Pictet Biopharmaceutical Mother0.38430.8181639363-34737-5.1531
2024-11-28Schwab US Small-Cap ETF™0.35840.04915964153360.0564
2024-10-31Vanguard Russell 2000 ETF0.32780.0649545490-3400-0.6194
2024-10-31BlackRock Advantage Small Cap Core Instl0.32540.195854151900
2024-09-30Vanguard Explorer Inv0.3150.035852417900
Total 17.844411.78429691900-194751-0.7%

5.3. Insider Transactions

Insiders are holding 0.547% of the shares of ACADIA Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-11-19James KiharaSELL407316.81
2024-11-19Mark C SchneyerSELL1025916.81
2024-11-19Brendan TeehanSELL1032916.81
2024-08-19Brendan TeehanSELL953415.28
2024-08-19Mark C SchneyerSELL973315.28
2024-08-19Stephen DavisSELL3174715.28
2024-06-10Mark C SchneyerSELL97514.79
2024-05-02Brendan TeehanSELL347716.94
2024-05-02James KiharaSELL132616.94
2024-05-02Mark C SchneyerSELL350316.94
2024-05-02Stephen DavisSELL1142716.94
2024-04-08Mark C SchneyerSELL271617.87
2024-04-08Stephen DavisSELL2657417.87
2024-04-08James KiharaSELL179017.87
2024-04-08Brendan TeehanSELL256817.87
2024-03-27Brendan TeehanSELL514017.9
2024-03-27Mark C SchneyerSELL543417.9
2024-03-27Stephen DavisSELL1771417.9
2024-02-26Brendan TeehanSELL62424.67
2024-02-26James KiharaSELL47424.67
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets976,868
Total Liabilities399,688
Total Stockholder Equity577,180
 As reported
Total Liabilities 399,688
Total Stockholder Equity+ 577,180
Total Assets = 976,868

Assets

Total Assets976,868
Total Current Assets788,284
Long-term Assets188,584
Total Current Assets
Cash And Cash Equivalents 155,149
Short-term Investments 410,181
Net Receivables 98,209
Inventory 61,041
Other Current Assets 63,704
Total Current Assets  (as reported)788,284
Total Current Assets  (calculated)788,284
+/-0
Long-term Assets
Property Plant Equipment 48,241
Intangible Assets 105,515
Long-term Assets Other 34,828
Long-term Assets  (as reported)188,584
Long-term Assets  (calculated)188,584
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities343,945
Long-term Liabilities55,743
Total Stockholder Equity577,180
Total Current Liabilities
Short-term Debt 8,949
Accounts payable 19,081
Other Current Liabilities 315,915
Total Current Liabilities  (as reported)343,945
Total Current Liabilities  (calculated)343,945
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt40,421
Long-term Liabilities Other 15,322
Long-term Liabilities  (as reported)55,743
Long-term Liabilities  (calculated)55,743
+/-0
Total Stockholder Equity
Common Stock16
Retained Earnings -2,348,128
Accumulated Other Comprehensive Income 858
Other Stockholders Equity 2,924,434
Total Stockholder Equity (as reported)577,180
Total Stockholder Equity (calculated)577,180
+/-0
Other
Capital Stock16
Cash and Short Term Investments 565,330
Common Stock Shares Outstanding 166,178
Liabilities and Stockholders Equity 976,868
Net Debt -105,779
Net Invested Capital 577,180
Net Working Capital 444,339
Property Plant and Equipment Gross 48,241
Short Long Term Debt Total 49,370



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312000-09-30
> Total Assets 
33,471
16,023
0
0
0
31,693
27,416
53,304
47,750
40,365
45,924
73,631
70,271
62,506
63,518
115,568
100,914
89,544
75,748
160,221
148,346
134,584
113,325
96,080
78,203
64,677
50,371
70,063
58,475
49,680
43,273
39,166
35,750
38,394
46,887
41,309
37,022
32,114
26,519
21,874
23,750
108,590
103,015
206,909
199,285
189,118
373,506
359,465
341,763
325,458
301,963
275,539
245,320
221,896
466,590
438,034
617,384
561,153
503,013
456,315
413,714
384,506
351,040
314,960
266,456
540,202
501,105
460,883
765,586
783,183
747,450
759,649
795,664
782,616
755,173
724,429
717,673
700,122
624,251
612,766
602,491
587,812
655,305
642,769
632,540
748,956
855,103
914,099
976,868
976,868914,099855,103748,956632,540642,769655,305587,812602,491612,766624,251700,122717,673724,429755,173782,616795,664759,649747,450783,183765,586460,883501,105540,202266,456314,960351,040384,506413,714456,315503,013561,153617,384438,034466,590221,896245,320275,539301,963325,458341,763359,465373,506189,118199,285206,909103,015108,59023,75021,87426,51932,11437,02241,30946,88738,39435,75039,16643,27349,68058,47570,06350,37164,67778,20396,080113,325134,584148,346160,22175,74889,544100,914115,56863,51862,50670,27173,63145,92440,36547,75053,30427,41631,69300016,02333,471
   > Total Current Assets 
0
0
0
0
0
28,272
23,690
50,258
44,905
37,818
43,653
71,398
68,000
60,125
61,121
112,661
97,804
85,783
72,365
156,893
144,951
131,253
110,170
93,107
75,535
62,382
48,287
68,214
56,804
48,473
42,267
38,318
34,992
37,849
46,548
41,015
36,763
31,949
26,387
21,775
23,685
108,548
102,985
206,761
198,675
188,360
372,820
358,854
341,065
324,618
299,899
273,393
242,847
218,989
462,352
423,897
603,490
547,897
489,753
443,745
401,972
373,477
340,014
301,096
254,116
526,106
476,406
436,940
742,330
760,250
724,421
735,735
730,213
717,616
673,984
645,730
640,917
617,823
542,223
532,519
521,552
507,937
502,850
492,628
499,170
616,125
675,296
728,916
788,284
788,284728,916675,296616,125499,170492,628502,850507,937521,552532,519542,223617,823640,917645,730673,984717,616730,213735,735724,421760,250742,330436,940476,406526,106254,116301,096340,014373,477401,972443,745489,753547,897603,490423,897462,352218,989242,847273,393299,899324,618341,065358,854372,820188,360198,675206,761102,985108,54823,68521,77526,38731,94936,76341,01546,54837,84934,99238,31842,26748,47356,80468,21448,28762,38275,53593,107110,170131,253144,951156,89372,36585,78397,804112,66161,12160,12568,00071,39843,65337,81844,90550,25823,69028,27200000
       Cash And Cash Equivalents 
0
4,454
0
0
0
6,308
4,368
8,157
5,693
8,302
11,236
15,812
23,353
9,796
11,264
38,420
26,229
15,480
22,315
39,631
23,462
16,987
21,005
20,285
22,213
21,171
18,840
17,984
17,322
18,122
18,067
8,811
9,656
6,849
6,829
8,020
8,317
6,889
5,558
9,208
8,016
57,899
18,436
24,247
11,803
11,707
96,455
13,698
36,369
61,854
76,424
93,212
70,799
102,138
175,220
131,774
153,679
163,620
157,383
143,789
112,616
69,418
116,328
74,182
63,897
134,758
97,557
74,432
385,474
189,680
173,059
310,441
452,352
326,028
304,487
266,956
94,640
147,435
204,920
139,833
154,842
114,846
290,895
107,941
98,193
188,657
204,745
177,134
155,149
155,149177,134204,745188,65798,193107,941290,895114,846154,842139,833204,920147,43594,640266,956304,487326,028452,352310,441173,059189,680385,47474,43297,557134,75863,89774,182116,32869,418112,616143,789157,383163,620153,679131,774175,220102,13870,79993,21276,42461,85436,36913,69896,45511,70711,80324,24718,43657,8998,0169,2085,5586,8898,3178,0206,8296,8499,6568,81118,06718,12217,32217,98418,84021,17122,21320,28521,00516,98723,46239,63122,31515,48026,22938,42011,2649,79623,35315,81211,2368,3025,6938,1574,3686,3080004,4540
       Short-term Investments 
0
7,985
0
0
0
20,906
18,126
40,636
37,465
27,626
30,410
53,148
39,378
33,205
32,420
55,715
68,428
67,775
47,584
114,238
117,500
109,871
85,494
69,336
50,485
38,912
27,544
48,168
37,587
28,938
22,509
25,464
22,570
30,238
38,835
32,341
27,833
24,159
20,366
12,141
15,042
50,068
83,027
181,204
184,377
174,083
272,830
340,755
301,430
260,632
221,469
177,565
169,892
112,994
282,023
280,781
435,180
365,416
312,098
273,531
254,009
271,924
181,735
182,673
150,239
338,762
316,767
307,455
298,373
507,749
478,347
348,110
192,089
305,930
273,281
289,962
445,651
373,271
241,057
296,518
281,737
301,977
111,978
267,437
247,727
250,208
265,775
323,808
410,181
410,181323,808265,775250,208247,727267,437111,978301,977281,737296,518241,057373,271445,651289,962273,281305,930192,089348,110478,347507,749298,373307,455316,767338,762150,239182,673181,735271,924254,009273,531312,098365,416435,180280,781282,023112,994169,892177,565221,469260,632301,430340,755272,830174,083184,377181,20483,02750,06815,04212,14120,36624,15927,83332,34138,83530,23822,57025,46422,50928,93837,58748,16827,54438,91250,48569,33685,494109,871117,500114,23847,58467,77568,42855,71532,42033,20539,37853,14830,41027,62637,46540,63618,12620,9060007,9850
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,930
1,934
0
0
0
0
0
0
0
0
0
0
0
0
0
1,642
1,320
1,139
964
746
1,508
206
1,638
783
1,633
5,224
7,140
9,519
12,378
15,254
18,430
23,348
26,682
20,682
27,789
33,770
32,722
32,269
37,874
44,571
46,128
47,784
50,282
57,390
51,820
61,668
65,344
63,482
68,889
56,136
63,080
70,250
84,156
94,532
102,350
100,079
110,393
98,209
98,209110,393100,079102,35094,53284,15670,25063,08056,13668,88963,48265,34461,66851,82057,39050,28247,78446,12844,57137,87432,26932,72233,77027,78920,68226,68223,34818,43015,25412,3789,5197,1405,2241,6337831,6382061,5087469641,1391,3201,64200000000000001,9342,9300000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,867
4,301
4,175
3,881
6,003
5,536
5,248
5,583
4,737
4,347
4,070
4,570
3,824
4,846
6,341
6,318
6,210
7,979
9,682
10,311
10,786
14,336
7,881
7,009
6,327
5,844
6,636
6,095
9,199
20,768
35,819
61,936
71,525
61,041
61,04171,52561,93635,81920,7689,1996,0956,6365,8446,3277,0097,88114,33610,78610,3119,6827,9796,2106,3186,3414,8463,8244,5704,0704,3474,7375,5835,2485,5366,0033,8814,1754,3012,8670000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
3,421
3,726
3,045
2,844
2,547
2,272
2,232
2,271
2,381
2,397
2,907
3,110
3,761
3,383
3,328
3,395
3,331
3,155
2,973
2,668
2,295
2,084
1,849
1,671
1,207
1,006
848
758
545
339
294
259
165
132
99
65
42
30
148
610
758
686
611
698
840
2,064
2,146
2,473
2,907
4,238
14,137
13,894
13,256
13,260
12,570
11,742
11,029
11,026
13,864
12,340
14,096
24,699
23,943
23,256
22,933
23,029
23,914
65,451
65,000
81,189
78,699
76,756
82,299
82,028
80,247
80,939
79,875
152,455
150,141
133,370
132,831
179,807
185,183
188,584
188,584185,183179,807132,831133,370150,141152,45579,87580,93980,24782,02882,29976,75678,69981,18965,00065,45123,91423,02922,93323,25623,94324,69914,09612,34013,86411,02611,02911,74212,57013,26013,25613,89414,1374,2382,9072,4732,1462,064840698611686758610148304265991321652592943395457588481,0061,2071,6711,8492,0842,2952,6682,9733,1553,3313,3953,3283,3833,7613,1102,9072,3972,3812,2712,2322,2722,5472,8443,0453,7263,42100000
       Property Plant Equipment 
2,880
2,419
0
0
0
3,117
2,801
2,761
2,549
2,547
2,272
2,232
2,249
2,283
2,299
2,811
3,014
3,505
3,287
3,141
3,095
3,048
2,919
2,712
2,420
2,103
1,846
1,657
1,498
1,062
870
698
622
426
244
208
181
151
121
92
63
42
30
92
490
579
543
500
520
553
1,786
1,813
2,068
2,203
2,623
2,897
3,159
3,081
3,471
3,296
2,991
2,662
2,709
2,760
3,372
3,309
14,655
14,245
13,208
12,704
13,702
14,567
56,659
56,444
72,868
70,568
68,613
66,315
65,717
64,433
63,134
61,594
59,746
57,575
55,642
56,467
58,650
56,534
48,241
48,24156,53458,65056,46755,64257,57559,74661,59463,13464,43365,71766,31568,61370,56872,86856,44456,65914,56713,70212,70413,20814,24514,6553,3093,3722,7602,7092,6622,9913,2963,4713,0813,1592,8972,6232,2032,0681,8131,78655352050054357949092304263921211511812082444266226988701,0621,4981,6571,8462,1032,4202,7122,9193,0483,0953,1413,2873,5053,0142,8112,2992,2832,2492,2322,2722,5472,5492,7612,8013,1170002,4192,880
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,900
1,182
1,300
1,100
1,100
1,800
2,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000002,3001,8001,1001,1001,3001,1822,900000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,754
7,385
7,015
6,646
6,277
5,907
5,538
5,169
4,800
4,431
4,062
3,692
3,323
2,954
2,585
2,215
1,846
1,477
1,108
738
369
0
0
0
0
0
0
69,583
68,219
66,855
65,490
110,204
107,859
105,515
105,515107,859110,20465,49066,85568,21969,5830000003697381,1081,4771,8462,2152,5852,9543,3233,6924,0624,4314,8005,1695,5385,9076,2776,6467,0157,3857,7540000000000000000000000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
304
925
285
295
0
0
0
22
98
98
96
96
256
96
187
300
283
236
261
248
192
238
192
173
145
136
150
136
119
95
86
78
14
11
7
2
-42
0
56
120
179
143
111
178
-97,917
278
333
405
704
1,615
3,486
3,350
3,160
3,143
2,997
2,844
2,829
3,148
3,404
3,355
5,425
5,252
5,275
5,294
5,344
6,312
6,301
6,315
6,148
1,813
1,992
2,373
6,614
10,541
10,044
12,035
5,311
23,126
24,347
10,873
5,104
10,953
15,020
34,828
34,82815,02010,9535,10410,87324,34723,1265,31112,03510,04410,5416,6142,3731,9921,8136,1486,3156,3016,3125,3445,2945,2755,2525,4253,3553,4043,1482,8292,8442,9973,1433,1603,3503,4861,615704405333278-97,917178111143179120560-4227111478869511913615013614517319223819224826123628330018796256969698982200029528592530400000
> Total Liabilities 
7,600
9,611
0
0
0
84,364
85,832
10,512
10,390
9,685
13,554
12,481
21,074
23,135
23,659
27,022
22,513
22,385
18,953
15,951
18,612
20,650
14,658
14,876
11,961
11,685
11,985
43,650
39,508
37,566
36,175
36,010
35,924
8,706
8,779
8,488
8,878
8,752
8,934
9,166
6,086
23,606
23,353
25,434
18,531
6,987
8,046
9,357
11,274
15,969
16,869
19,718
17,974
22,134
21,339
29,219
39,326
42,742
45,489
41,175
36,388
49,221
46,871
50,240
43,016
61,123
82,749
71,969
76,297
84,048
109,068
96,636
140,797
155,607
173,567
159,591
150,718
159,228
179,454
177,918
176,805
187,399
281,047
246,976
270,366
317,201
391,059
397,399
399,688
399,688397,399391,059317,201270,366246,976281,047187,399176,805177,918179,454159,228150,718159,591173,567155,607140,79796,636109,06884,04876,29771,96982,74961,12343,01650,24046,87149,22136,38841,17545,48942,74239,32629,21921,33922,13417,97419,71816,86915,96911,2749,3578,0466,98718,53125,43423,35323,6066,0869,1668,9348,7528,8788,4888,7798,70635,92436,01036,17537,56639,50843,65011,98511,68511,96114,87614,65820,65018,61215,95118,95322,38522,51327,02223,65923,13521,07412,48113,5549,68510,39010,51285,83284,3640009,6117,600
   > Total Current Liabilities 
2,968
6,153
0
0
0
8,226
10,441
9,565
9,364
8,641
11,693
11,078
19,689
21,701
21,743
25,306
20,767
20,534
17,272
14,326
17,155
19,287
13,472
13,889
11,202
11,051
11,436
20,936
15,248
14,707
13,550
12,984
13,168
5,959
6,139
5,947
6,409
6,165
6,433
6,760
6,086
5,948
5,695
7,776
7,870
6,979
8,033
9,339
11,253
15,834
16,651
19,378
17,735
21,902
21,122
29,022
39,149
42,585
45,265
40,913
36,143
49,030
46,089
49,214
41,807
59,565
74,983
63,814
67,744
74,826
99,741
86,422
91,856
105,967
109,373
95,328
88,218
96,068
119,603
117,681
116,570
125,630
224,301
187,942
209,603
254,254
330,597
337,851
343,945
343,945337,851330,597254,254209,603187,942224,301125,630116,570117,681119,60396,06888,21895,328109,373105,96791,85686,42299,74174,82667,74463,81474,98359,56541,80749,21446,08949,03036,14340,91345,26542,58539,14929,02221,12221,90217,73519,37816,65115,83411,2539,3398,0336,9797,8707,7765,6955,9486,0866,7606,4336,1656,4095,9476,1395,95913,16812,98413,55014,70715,24820,93611,43611,05111,20213,88913,47219,28717,15514,32617,27220,53420,76725,30621,74321,70119,68911,07811,6938,6419,3649,56510,4418,2260006,1532,968
       Short-term Debt 
0
0
0
0
0
3,242
3,167
2,604
2,059
1,486
845
855
926
890
805
826
902
996
1,039
1,047
1,017
978
934
882
815
795
685
560
450
365
291
161
111
78
44
40
37
32
22
13
3
0
0
0
0
0
0
0
0
2,822
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,468
4,412
3,889
3,434
2,909
2,653
3,857
5,087
6,082
7,521
8,150
8,304
8,944
9,024
9,231
9,305
9,173
9,058
9,031
9,405
10,453
10,470
8,949
8,94910,47010,4539,4059,0319,0589,1739,3059,2319,0248,9448,3048,1507,5216,0825,0873,8572,6532,9093,4343,8894,4124,46800000000000000002,822000000003132232374044781111612913654505606857958158829349781,0171,0471,0399969028268058909268558451,4862,0592,6043,1673,24200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000004,468000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
379
1,121
0
0
0
1,533
2,530
1,985
2,450
2,153
1,357
2,317
1,730
2,073
733
3,419
3,206
3,387
3,058
2,273
2,950
2,590
2,047
3,217
2,450
2,283
4,185
3,981
2,554
2,947
2,122
2,300
2,617
1,972
1,380
1,139
1,262
1,960
1,035
757
1,131
1,375
1,396
1,177
1,120
372
1,562
1,104
1,110
2,016
2,518
2,916
2,204
1,672
1,307
1,024
2,828
3,912
2,166
3,588
2,962
8,786
2,996
3,333
2,955
3,167
3,275
4,650
3,444
7,222
6,623
6,466
3,471
8,493
8,849
9,065
7,722
6,876
10,768
11,854
10,008
12,746
17,422
18,811
12,310
17,543
19,332
19,882
19,081
19,08119,88219,33217,54312,31018,81117,42212,74610,00811,85410,7686,8767,7229,0658,8498,4933,4716,4666,6237,2223,4444,6503,2753,1672,9553,3332,9968,7862,9623,5882,1663,9122,8281,0241,3071,6722,2042,9162,5182,0161,1101,1041,5623721,1201,1771,3961,3751,1317571,0351,9601,2621,1391,3801,9722,6172,3002,1222,9472,5543,9814,1852,2832,4503,2172,0472,5902,9502,2733,0583,3873,2063,4197332,0731,7302,3171,3572,1532,4501,9852,5301,5330001,121379
       Other Current Liabilities 
1,260
2,057
0
0
0
2,131
2,423
2,990
3,201
3,681
3,657
3,405
12,865
15,292
16,164
17,145
13,868
13,485
10,050
8,510
11,524
15,012
10,321
9,620
7,767
7,535
6,474
7,270
6,340
5,358
5,048
4,128
3,760
3,219
4,253
4,015
4,402
3,504
4,693
5,225
4,686
4,139
4,159
6,488
6,670
6,552
6,429
8,206
10,128
13,818
14,133
16,462
15,531
20,230
19,815
27,485
34,445
36,029
38,967
37,325
33,181
40,244
43,093
45,881
38,852
56,398
67,240
54,752
60,411
64,170
90,209
77,303
84,528
92,387
94,442
78,742
72,346
80,888
99,891
96,803
97,331
103,579
197,706
169,131
197,293
225,742
293,221
299,043
315,915
315,915299,043293,221225,742197,293169,131197,706103,57997,33196,80399,89180,88872,34678,74294,44292,38784,52877,30390,20964,17060,41154,75267,24056,39838,85245,88143,09340,24433,18137,32538,96736,02934,44527,48519,81520,23015,53116,46214,13313,81810,1288,2066,4296,5526,6706,4884,1594,1394,6865,2254,6933,5044,4024,0154,2533,2193,7604,1285,0485,3586,3407,2706,4747,5357,7679,62010,32115,01211,5248,51010,05013,48513,86817,14516,16415,29212,8653,4053,6573,6813,2012,9902,4232,1310002,0571,260
   > Long-term Liabilities 
0
0
0
0
0
76,138
75,391
946
1,026
1,044
1,861
1,403
1,385
1,433
1,916
1,716
1,746
1,851
1,681
1,625
1,457
1,363
1,186
987
759
634
549
22,714
24,260
22,859
22,625
23,026
22,756
2,747
2,640
2,541
2,469
2,587
2,501
2,406
0
17,658
17,658
17,658
10,661
8
13
18
21
135
218
340
239
232
217
197
177
157
224
262
245
191
782
1,026
1,209
1,558
7,766
8,155
8,553
9,222
9,327
10,214
48,941
49,640
64,194
64,263
62,500
63,160
59,851
60,237
60,235
61,769
56,746
59,034
60,763
62,947
60,462
59,548
55,743
55,74359,54860,46262,94760,76359,03456,74661,76960,23560,23759,85163,16062,50064,26364,19449,64048,94110,2149,3279,2228,5538,1557,7661,5581,2091,026782191245262224157177197217232239340218135211813810,66117,65817,65817,65802,4062,5012,5872,4692,5412,6402,74722,75623,02622,62522,85924,26022,7145496347599871,1861,3631,4571,6251,6811,8511,7461,7161,9161,4331,3851,4031,8611,0441,02694675,39176,13800000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,658
17,658
17,658
10,659
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000010,65917,65817,65817,65800000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
1,007
584
458
542
1,183
883
602
472
178
186
202
207
247
257
199
204
225
22,486
24,106
22,761
22,560
22,975
22,715
2,715
2,617
2,528
2,467
2,587
2,501
2,406
0
0
0
0
2
8
13
18
21
135
218
340
239
232
217
197
177
157
224
262
245
191
782
1,026
1,209
1,558
1,012
1,413
2,174
2,861
3,237
4,545
3,598
5,180
3,613
5,129
4,823
7,034
4,373
5,544
6,466
9,074
5,305
0
12,660
0
0
0
0
000012,66005,3059,0746,4665,5444,3737,0344,8235,1293,6135,1803,5984,5453,2372,8612,1741,4131,0121,5581,2091,0267821912452622241571771972172322393402181352118138200002,4062,5012,5872,4672,5282,6172,71522,71522,97522,56022,76124,10622,4862252041992572472072021861784726028831,1835424585841,0070000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,481
2,441
2,587
2,501
2,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000002,4062,5012,5872,4412,48100000000000000000000000000000000000
> Total Stockholder Equity
25,871
6,412
0
0
0
-52,671
-58,415
42,792
37,359
30,680
32,371
61,150
49,197
39,371
39,859
88,546
78,401
67,159
56,795
144,270
129,734
113,934
98,667
81,204
66,242
52,992
38,386
26,413
18,967
12,114
7,098
3,156
-174
29,688
38,108
32,821
28,144
23,362
17,585
12,708
17,664
84,984
79,662
181,475
180,754
182,131
365,460
350,108
330,489
309,489
285,094
255,821
227,346
199,762
445,251
408,815
578,058
518,411
457,524
415,140
377,326
335,285
304,169
264,720
223,440
479,079
418,356
388,914
689,289
699,135
638,382
663,013
654,867
627,009
581,606
564,838
566,955
540,894
444,797
434,848
425,686
400,413
374,258
395,793
362,174
431,755
464,044
516,700
577,180
577,180516,700464,044431,755362,174395,793374,258400,413425,686434,848444,797540,894566,955564,838581,606627,009654,867663,013638,382699,135689,289388,914418,356479,079223,440264,720304,169335,285377,326415,140457,524518,411578,058408,815445,251199,762227,346255,821285,094309,489330,489350,108365,460182,131180,754181,47579,66284,98417,66412,70817,58523,36228,14432,82138,10829,688-1743,1567,09812,11418,96726,41338,38652,99266,24281,20498,667113,934129,734144,27056,79567,15978,40188,54639,85939,37149,19761,15032,37130,68037,35942,792-58,415-52,6710006,41225,871
   Common Stock
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
6
7
7
8
9
9
10
10
10
10
10
10
10
10
11
11
12
12
12
12
12
12
12
12
12
14
14
14
15
15
15
15
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
16
161616161616161616161616161616161615151515141414121212121212121212111110101010101010109987765555554444444444444443333222222220000000
   Retained Earnings Total Equity000000-2,412,5720-2,327,826-2,300,643-2,266,632-2,153,576-2,110,482-2,096,025-2,052,154-1,985,706-1,918,946-1,834,286-1,792,145-1,704,122-1,651,086-1,609,108-1,554,167-1,468,863-1,403,371-1,341,233-1,277,967-1,223,671-1,154,801-1,089,553-1,022,112-933,979-855,283-783,670-712,348-662,586-616,802-577,896-538,518-498,143-469,777-444,991-423,496-405,668-393,619-382,924-373,843-367,720-360,910-358,508-353,089-346,871-341,571-336,49500000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-2,499
-3,660
-3,102
-2,467
-1,793
-1,445
-1,188
-936
-639
-168
42
194
176
187
297
433
493
668
307
148
273
92
100
197
483
469
401
528
512
537
10
6
9
6
3
4
4
15
-26
84
48
0
94
77
-9
4
11
45
11
316
206
533
106
94
-97
-73
-399
-699
-500
-314
-372
207
554
420
297
1,525
1,480
509
36
34
38
-1
-192
-612
-843
-1,365
-975
-220
-535
-319
24
-229
-339
858
858-339-22924-319-535-220-975-1,365-843-612-192-13834365091,4801,525297420554207-372-314-500-699-399-73-97941065332063161145114-9779404884-2615443696105375125284014694831971009227314830766849343329718717619442-168-639-936-1,188-1,445-1,793-2,467-3,102-3,660-2,49900000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
369,301
369,704
370,219
370,663
371,208
378,564
452,693
453,483
564,417
574,280
587,742
788,946
794,995
800,179
807,631
823,598
833,696
844,093
862,327
1,157,272
1,192,268
1,432,796
1,452,272
1,479,530
1,504,778
1,532,188
1,559,343
1,582,823
1,606,441
1,627,113
1,948,300
1,972,302
1,997,454
2,339,940
2,402,945
2,428,987
2,495,804
2,573,288
2,612,663
2,633,710
2,660,809
2,677,422
2,694,646
2,712,025
2,736,318
2,754,861
0
2,787,034
0
0
0
0
0
0
0000002,787,03402,754,8612,736,3182,712,0252,694,6462,677,4222,660,8092,633,7102,612,6632,573,2882,495,8042,428,9872,402,9452,339,9401,997,4541,972,3021,948,3001,627,1131,606,4411,582,8231,559,3431,532,1881,504,7781,479,5301,452,2721,432,7961,192,2681,157,272862,327844,093833,696823,598807,631800,179794,995788,946587,742574,280564,417453,483452,693378,564371,208370,663370,219369,704369,30100000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
18,194
20,091
126,626
126,773
126,755
133,686
168,244
168,345
168,426
177,910
238,254
239,220
240,446
242,625
340,742
342,115
343,293
344,231
345,416
346,227
346,815
347,391
348,137
349,322
350,872
351,357
351,771
352,541
353,278
367,505
369,301
369,704
370,219
370,663
371,208
378,564
452,693
453,483
564,417
574,280
587,742
788,946
794,995
800,179
807,631
823,598
833,696
844,093
862,327
1,157,272
1,192,268
1,432,796
1,452,272
1,479,530
1,504,778
1,532,188
1,559,343
1,582,823
1,606,441
1,627,113
1,948,300
1,972,302
1,997,454
2,339,940
2,402,945
2,428,987
2,495,804
2,573,288
2,612,663
2,633,710
2,660,809
2,677,422
2,694,646
2,712,025
2,736,318
2,754,861
2,770,923
2,787,034
2,807,770
2,839,111
2,862,552
2,878,539
2,897,916
2,924,434
2,924,4342,897,9162,878,5392,862,5522,839,1112,807,7702,787,0342,770,9232,754,8612,736,3182,712,0252,694,6462,677,4222,660,8092,633,7102,612,6632,573,2882,495,8042,428,9872,402,9452,339,9401,997,4541,972,3021,948,3001,627,1131,606,4411,582,8231,559,3431,532,1881,504,7781,479,5301,452,2721,432,7961,192,2681,157,272862,327844,093833,696823,598807,631800,179794,995788,946587,742574,280564,417453,483452,693378,564371,208370,663370,219369,704369,301367,505353,278352,541351,771351,357350,872349,322348,137347,391346,815346,227345,416344,231343,293342,115340,742242,625240,446239,220238,254177,910168,426168,345168,244133,686126,755126,773126,62620,09118,19400000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.